Skip to main content
57th ASAM Annual Conference Main banner
Final Program


Preview Program
Feedback

Focus Session

Beyond Kratom: Novel Products Containing 7-OH, Pseudo, MGM, and Kava

Sunday, April 26, 2026
8:30 AM - 9:45 AM PT
Location: Harbor D-F, Level 2
"Gas station heroin?" and "legal morphine?" Think again! In this session we myth-bust and dismantle the pejorative language used to describe kratom-derived products consumed by millions of adults. This session synthesizes epidemiological findings, real-world case reports, preclinical literature, and emerging data to inform attendees about kratom-derived products relevant to their practice. These include products containing 7-hydroxymitragynine ("7-OH"), mitragynine pseudoindoxyl ("pseudo"), kratom-kava products, and emerging MGM analogues. Recommendations are given for how substance use disorder assessment, diagnosis, and treatment can improve.

Learning Objectives:

Learners will be able to:
  • Upon completion, participants will be able to describe the basic pharmacology, toxicology, effects, risks, and benefits associated with kratom and kratom-derived products.
  • Upon completion, participants will be able to conduct highly specified clinical assessments, as well as better diagnosis and manage SUDs related to kratom-derived products in a data-informed and patient-centered manner.
  • Upon completion, participants will be able to define the dynamic state and federal policy and regulatory landscape surrounding kratom and kratom-derived products.
Disclosure(s):
Katherine Hill, MPH: PS Law Group: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
Kirsten E. Smith, PhD, LMSW: International Plant and Herbal Alliance: Consultant/Advisory Board (Terminated); Todd, Brown, and Frost: Consultant/Advisory Board (Terminated)
Edward W. Boyer, MD PhD: No financial relationships to disclose